Polestar Q3 retail sales rise 1% to 14,371 cars
Bitget2026/10/08 11:05Polestar posted record retail sales of 44,790 cars in the first nine months of 2026, up 0.6% year on year. Third-quarter retail sales reached 14,371 cars, up 1%, marking its strongest Q3 on record. Retail sales excluding the U.S. totaled 40,773 cars in the first nine months, down 0.5%. Ex-U.S. retail sales in Q3 were 12,211 cars, down 8%. Customer deliveries of the Polestar 5 began; the Polestar 4 SUV launch expanded its lineup into the D-SUV segment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polestar Automotive Holding UK plc published the original content used to generate this news brief on October 08, 2026, and is solely responsible for the information contained therein.
- Polestar posted record retail sales of 44,790 cars in the first nine months of 2026, up 0.6% year on year.
- Third-quarter retail sales reached 14,371 cars, up 1%, marking its strongest Q3 on record.
- Retail sales excluding the U.S. totaled 40,773 cars in the first nine months, down 0.5%.
- Ex-U.S. retail sales in Q3 were 12,211 cars, down 8%.
- Customer deliveries of the Polestar 5 began; the Polestar 4 SUV launch expanded its lineup into the D-SUV segment.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
